Valuation: Psychemedics Corporation

Market Cap 97.91L 89.18L 82.17L 74.75L 1.4Cr 91Cr 1.47Cr 10Cr 3.97Cr 50Cr 3.67Cr 3.6Cr 155.42Cr P/E 2023
-4.09x
P/E 2024 -7x
Enterprise Value 95.4L 86.89L 80.07L 72.83L 1.37Cr 88Cr 1.44Cr 9.74Cr 3.87Cr 48Cr 3.58Cr 3.5Cr 151.43Cr EV / Sales 2023
0.79x
EV / Sales 2024 0.68x
Free-Float
44.15%
Yield 2023
2.36%
Yield 2024 -
1 week-3.61%
Current month-3.61%
1 month-3.61%
3 months-3.61%
Current year+50.00%
Current year 1.33
Extreme 1.33
2.7
1 year 1.33
Extreme 1.33
2.7
3 years 1.11
Extreme 1.11
3.93
5 years 1.11
Extreme 1.11
8.8
10 years 1.11
Extreme 1.11
27.99
Manager TitleAgeSince
Chief Executive Officer 59 17/08/2023
Director of Finance/CFO 36 27/11/2023
Corporate Officer/Principal 40 21/09/2023
Director TitleAgeSince
Director/Board Member 64 16/03/2021
Director/Board Member 58 04/04/2022
Director/Board Member 64 12/08/2022
Date Insider Type Main position Quantity % Market Cap. Importance
13/12/24
Powell Anderson Capital Partners
BuyCompany 1,59,700 2.7093%
10/12/24
Powell Anderson Capital Partners
BuyCompany 86,991 1.4758%
10/12/24 Sell

Director

3,20,708 5.4408%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.61%+17.65%+14.29% 1.53Cr
+1.00%-9.52%+6.31%+18.43% 10TCr
+3.31%-4.70%-0.15%+91.45% 9.93TCr
-5.70%-14.32%+21.21%+399.00% 3.96TCr
-0.73%-0.48%+14.07%+94.82% 3.18TCr
-0.47%-0.90%+40.41%+73.91% 2.98TCr
-0.31%-0.51%+37.67%+91.53% 2.84TCr
-0.15%-7.99%+40.98%+305.22% 2.09TCr
-0.62%-2.67%-15.69%-20.65% 1.94TCr
0.00%-0.38%-2.83%+32.77% 1.7TCr
Average -0.37%-4.09%+15.96%+110.08% 4TCr
Weighted average by Cap. +0.37%-5.85%+12.08%+105.63%

Financials

2023 2024
Net sales 2.21Cr 2.01Cr 1.85Cr 1.69Cr 3.16Cr 204.63Cr 3.33Cr 23Cr 8.97Cr 111.77Cr 8.29Cr 8.12Cr 350.77Cr 1.97Cr 1.79Cr 1.65Cr 1.5Cr 2.82Cr 182.28Cr 2.96Cr 20Cr 7.99Cr 100Cr 7.39Cr 7.23Cr 312.47Cr
Net income -41.54L -37.83L -34.86L -31.71L -59.49L -38Cr -62.53L -4.24Cr -1.69Cr -21Cr -1.56Cr -1.53Cr -66Cr -18.61L -16.95L -15.62L -14.21L -26.65L -17Cr -28.01L -1.9Cr -75.55L -9.41Cr -69.82L -68.35L -30Cr
Net Debt 3L 3L 3L 3L 5L 3.09Cr 5L 34.12L 13.56L 1.69Cr 12.53L 12.27L 5.3Cr -3L -2L -2L -2L -4L -2.32Cr -4L -25.64L -10.19L -1.27Cr -9L -9L -3.98Cr
Projected Income Statement - Annual - Psychemedics Corporation
Logo Psychemedics Corporation
Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet.
Employees
101
  1. Stock Market
  2. Stocks
  3. PMDI Stock